The iPSCs generated from JMML harboring PTPN11 or CBL mutation have differential responses to the MEK inhibitors and JAK inhibitors owing to the activation of specific signaling pathways [70]. The gene discussed is PTPN11; the disease is juvenile myelomonocytic leukemia.